Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 4
1994 1
1995 6
1996 2
1997 7
1998 2
1999 2
2000 4
2001 4
2002 8
2003 7
2004 5
2005 6
2006 7
2007 12
2008 20
2009 9
2010 14
2011 20
2012 18
2013 20
2014 20
2015 26
2016 21
2017 17
2018 17
2019 22
2020 24
2021 14
2022 20
2023 15
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Results by year

Filters applied: . Clear all
Page 1
Challenges in neoantigen-directed therapeutics.
Lybaert L, Lefever S, Fant B, Smits E, De Geest B, Breckpot K, Dirix L, Feldman SA, van Criekinge W, Thielemans K, van der Burg SH, Ott PA, Bogaert C. Lybaert L, et al. Among authors: van der burg sh. Cancer Cell. 2023 Jan 9;41(1):15-40. doi: 10.1016/j.ccell.2022.10.013. Epub 2022 Nov 10. Cancer Cell. 2023. PMID: 36368320 Free article. Review.
Therapeutic cancer vaccines.
Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Saxena M, et al. Among authors: van der burg sh. Nat Rev Cancer. 2021 Jun;21(6):360-378. doi: 10.1038/s41568-021-00346-0. Epub 2021 Apr 27. Nat Rev Cancer. 2021. PMID: 33907315 Review.
CD47/SIRPα axis: bridging innate and adaptive immunity.
van Duijn A, Van der Burg SH, Scheeren FA. van Duijn A, et al. Among authors: van der burg sh. J Immunother Cancer. 2022 Jul;10(7):e004589. doi: 10.1136/jitc-2022-004589. J Immunother Cancer. 2022. PMID: 35831032 Free PMC article. Review.
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, Thor Straten P, Martínez-Ricarte F, Ponsati B, Okada H, Lassen U, Admon A, Ottensmeier CH, Ulges A, Kreiter S, von Deimling A, Skardelly M, Migliorini D, Kroep JR, Idorn M, Rodon J, Piró J, Poulsen HS, Shraibman B, McCann K, Mendrzyk R, Löwer M, Stieglbauer M, Britten CM, Capper D, Welters MJP, Sahuquillo J, Kiesel K, Derhovanessian E, Rusch E, Bunse L, Song C, Heesch S, Wagner C, Kemmer-Brück A, Ludwig J, Castle JC, Schoor O, Tadmor AD, Green E, Fritsche J, Meyer M, Pawlowski N, Dorner S, Hoffgaard F, Rössler B, Maurer D, Weinschenk T, Reinhardt C, Huber C, Rammensee HG, Singh-Jasuja H, Sahin U, Dietrich PY, Wick W. Hilf N, et al. Among authors: van der burg sh. Nature. 2019 Jan;565(7738):240-245. doi: 10.1038/s41586-018-0810-y. Epub 2018 Dec 19. Nature. 2019. PMID: 30568303 Clinical Trial.
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.
Haake M, Haack B, Schäfer T, Harter PN, Mattavelli G, Eiring P, Vashist N, Wedekink F, Genssler S, Fischer B, Dahlhoff J, Mokhtari F, Kuzkina A, Welters MJP, Benz TM, Sorger L, Thiemann V, Almanzar G, Selle M, Thein K, Späth J, Gonzalez MC, Reitinger C, Ipsen-Escobedo A, Wistuba-Hamprecht K, Eichler K, Filipski K, Zeiner PS, Beschorner R, Goedemans R, Gogolla FH, Hackl H, Rooswinkel RW, Thiem A, Roche PR, Joshi H, Pühringer D, Wöckel A, Diessner JE, Rüdiger M, Leo E, Cheng PF, Levesque MP, Goebeler M, Sauer M, Nimmerjahn F, Schuberth-Wagner C, von Felten S, Mittelbronn M, Mehling M, Beilhack A, van der Burg SH, Riedel A, Weide B, Dummer R, Wischhusen J. Haake M, et al. Among authors: van der burg sh. Nat Commun. 2023 Jul 20;14(1):4253. doi: 10.1038/s41467-023-39817-3. Nat Commun. 2023. PMID: 37474523 Free PMC article.
PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance.
van Gulijk M, van Krimpen A, Schetters S, Eterman M, van Elsas M, Mankor J, Klaase L, de Bruijn M, van Nimwegen M, van Tienhoven T, van Ijcken W, Boon L, van der Schoot J, Verdoes M, Scheeren F, van der Burg SH, Lambrecht BN, Stadhouders R, Dammeijer F, Aerts J, van Hall T. van Gulijk M, et al. Among authors: van der burg sh. Sci Immunol. 2023 May 19;8(83):eabn6173. doi: 10.1126/sciimmunol.abn6173. Epub 2023 May 19. Sci Immunol. 2023. PMID: 37205768
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. van Montfoort N, et al. Among authors: van der burg sh. Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29. Cell. 2018. PMID: 30503208 Free PMC article.
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert L, Thielemans K, Feldman SA, van der Burg SH, Bogaert C, Ott PA. Lybaert L, et al. Among authors: van der burg sh. Trends Cancer. 2023 Jun;9(6):503-519. doi: 10.1016/j.trecan.2023.02.004. Epub 2023 Apr 11. Trends Cancer. 2023. PMID: 37055237 Review.
Therapeutic cancer vaccines.
Melief CJ, van Hall T, Arens R, Ossendorp F, van der Burg SH. Melief CJ, et al. Among authors: van der burg sh. J Clin Invest. 2015 Sep;125(9):3401-12. doi: 10.1172/JCI80009. Epub 2015 Jul 27. J Clin Invest. 2015. PMID: 26214521 Free PMC article. Review.
Neoantigen Targetability in Progressive Advanced Melanoma.
van den Bulk J, Verdegaal EME, van der Ploeg M, Visser M, Nunes JB, de Ru AH, Tjokrodirijo RTN, Ijsselsteijn ME, Janssen NI, van der Breggen R, de Bruin L, de Kok P, Janssen GMC, Ruano D, Kapiteijn EHW, van Veelen PA, de Miranda NFCC, van der Burg SH. van den Bulk J, et al. Among authors: van der burg sh. Clin Cancer Res. 2023 Oct 13;29(20):4278-4288. doi: 10.1158/1078-0432.CCR-23-1106. Clin Cancer Res. 2023. PMID: 37540567 Free PMC article.
335 results